Editas Medicine (EDIT) Change in Receivables (2015 - 2025)
Editas Medicine (EDIT) reported Change in Receivables of $7.5 million for Q3 2025, up 6491.53% year-over-year from $114419.6 in Q3 2024, and up 9569.23% quarter-over-quarter from $78000.0 in Q2 2025.
Editas Medicine (EDIT) Change in Receivables (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Change in Receivables data on file, last reported at $7.5 million in Q3 2025.
- Change in Receivables for Q3 2025 came in at $7.5 million, up 6491.53% year-over-year; the trailing twelve-month figure through Sep 2025 was $8.0 million (up 448.61% YoY), and the FY2024 annual result was $6.1 million, up 20.57% from the prior year.
- Change in Receivables improved to $7.5 million in Q3 2025 per EDIT's latest filing, from $78000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $16.1 million in Q4 2024 and troughed at -$15.8 million in Q1 2025.
- A 5-year average of $109578.9 and a median of -$1000.0 in 2024 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2021 and 2022: Change in Receivables sank 1133.33% in 2021, then surged 31306.25% in 2022.
- A 5-year view of Change in Receivables shows it stood at $16000.0 in 2021, then surged by 31306.25% to $5.0 million in 2022, then surged by 54.53% to $7.8 million in 2023, then jumped by 107.86% to $16.1 million in 2024, then sank by 53.27% to $7.5 million in 2025.
- Business Quant data shows EDIT's Change in Receivables at $7.5 million in Q3 2025, $78000.0 in Q2 2025, and -$15.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.54 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | -15.76 Mn |
| Mar 31, 2025 | -15.76 Mn |
| Dec 31, 2024 | 16.14 Mn |
| Dec 31, 2024 | 16.14 Mn |
| Sep 30, 2024 | -118,000.00 |
| Sep 30, 2024 | -118,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -9.94 Mn |
| Mar 31, 2024 | -9.94 Mn |
| Dec 31, 2023 | 7.77 Mn |
| Dec 31, 2023 | 7.77 Mn |
| Sep 30, 2023 | 136,000.00 |
| Sep 30, 2023 | 136,000.00 |
| Jun 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 2.04 Mn |